dabigatran has been researched along with Kidney Failure in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 35 (89.74) | 24.3611 |
| 2020's | 4 (10.26) | 2.80 |
| Authors | Studies |
|---|---|
| Eikelboom, JW; Elsaesser, A; Glund, S; Hylek, EM; Pollack, CV; Reilly, P; van Ryn, J; Weitz, JI | 1 |
| Młodawska, E; Sobkowicz, B; Tomaszuk-Kazberuk, A; van Ryn, J; Łopatowska, P | 1 |
| Damulevičienė, G; Galaunė, V; Gumbrevičius, G; Gumbrevičiūtė, M | 1 |
| Lobastov, KV; Schastlivtsev, IV | 1 |
| Ageno, W; Casella, IB; Chee, KH; Desch, M; Goldhaber, SZ; Schellong, S; Schulman, S; Singer, DE; Tang, W; Voccia, I; Zint, K | 1 |
| Medlicott, NJ; Reith, DM; Simpson, BH; Smith, AJ | 1 |
| Cuccia, C; Enea, I; Fresco, C; Paciaroni, M; Patti, G; Pecora, D; Rocca, B; Rubboli, A | 1 |
| Brodmann, M; Gary, T; Hackl, G; Jud, P; Portugaller, R; Tiesenhausen, K | 1 |
| Gradišek, P; Krevel, B; Mavri, A; Mijovski, MB; Stecher, A; Vene, N | 1 |
| Burnett, AE; Dobesh, PP; Fanikos, J; Mahan, CE | 1 |
| Gersh, BJ; Noseworthy, PA; Sangaralingham, LR; Shah, ND; Yao, X | 1 |
| Albendin Iglesias, H; Andreu Cayuelas, JM; Bailen Lorenzo, JL; Caro Martínez, C; Cerezo Manchado, JJ; Elvira Ruiz, G; Flores Blanco, PJ; García Alberola, A; Januzzi, JL; Manzano-Fernández, S | 1 |
| Gan, G; Glund, S; Grottke, O; Honickel, M; Moschetti, V; Reilly, P; Van Ryn, J | 1 |
| Brennan, Y; Curnow, J; Favaloro, EJ; Keenan, H; Pasalic, L | 1 |
| Padrini, R | 1 |
| Gómez-Mantilla, JD; Hanke, N; Lehr, T; Maas, H; Moj, D; Schaeftlein, A | 1 |
| Schulman, S | 1 |
| Bock, F; Hartung, K; Isermann, B; Meyer, F | 1 |
| Dalmau, FG | 1 |
| Attia, JR; Pearce, R | 1 |
| Böhm, M; Dichgans, M; Diener, HC; Ell, C; Endres, M; Epple, C; Grond, M; Laufs, U; Nickenig, G; Riess, H; Röther, J; Schellinger, PD; Spannagl, M; Steiner, T; Veltkamp, R | 1 |
| Assayag, P; Berthelot, E; Desconclois, C; Lavenu-Bombled, C; Orostegui-Giron, L | 1 |
| Chan, BS; Chiew, AL; Khamoudes, D | 1 |
| Chatterjee, S; Halperin, JL; Herzog, E; Mukherjee, D; Nairooz, R; Sardar, P | 1 |
| Hvas, AM; Skjødt-Jensen, AM | 1 |
| Bender, J; Bryant, G; Koenigsfeld, C; Lehman, N; Logemann, C; Sayler, M | 1 |
| Brueckmann, M; Clemens, A; Feuring, M; Frostick, SP; Gullberg, J; Kleine, E; Rosencher, N; Samama, CM | 1 |
| De Smet, M; Gansser, D; Glund, S; Haazen, W; Kreuzer, J; Lang, B; Moschetti, V; Norris, S; Reilly, P; Schmohl, M; Stangier, J; van Ryn, J | 1 |
| Barra, ME; Connors, JM; Fanikos, J; Goldhaber, SZ; Piazza, G; Sylvester, KW | 1 |
| Amiral, J; Eriksson, BI; Feuring, M; Haertter, S; Mikuska, Z; Nehmiz, G; Stangier, J; Weitz, JI | 1 |
| Ako, J; Fujiishi, T; Fukaya, H; Horiguchi, A; Igarashi, T; Ishizue, N; Kishihara, J; Murakami, M; Nakamura, H; Nishinarita, R; Niwano, S; Oikawa, J; Satoh, A; Yoshizawa, T | 1 |
| Barrera, LH; Ceresetto, J; Duboscq, C; Girardi, B; Hoyhamburu, J; López, MS; Martinuzzo, ME; Otaso, JC; Otero, V; Penchasky, D; Stemmelin, G; Viñuales, ES | 1 |
| Glund, S; Haazen, W; Harada, A; Ikushima, I; Imazu, S; Lang, B; Moschetti, V; Norris, S; Ramael, S; Reilly, PA; Stangier, J | 1 |
| Mazur, D; Rathgen, K; Stähle, H; Stangier, J | 1 |
| Clemens, A; Dahl, OE; Eriksson, BI; Kurth, AA; Noack, H; Rosencher, N | 1 |
| Bell, S; Dawes, M; Nand, J; Spriggs, D; Young, L | 1 |
| Tripodi, A | 1 |
| Crowther, MA; Siegal, DM | 1 |
11 review(s) available for dabigatran and Kidney Failure
| Article | Year |
|---|---|
[Peculiarities of the treatment of venous thromboembolism with direct oral anticoagulants in challenging patients: senile age, renal failure, fragility].
Topics: Administration, Oral; Age Factors; Aged; Antithrombins; Dabigatran; Frail Elderly; Humans; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Venous Thromboembolism | 2020 |
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Pharmaceutical Research; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin | 2017 |
Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Renal Insufficiency; Rivaroxaban | 2019 |
New anticoagulants in atrial fibrillation management.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Coumarins; Dabigatran; Female; Hematology; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Insufficiency; Sex Factors; Warfarin | 2013 |
[From heparin to apixaban: anticoagulants cut both ways?].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Blood Coagulation Tests; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Fondaparinux; Heparin; Humans; International Normalized Ratio; Liver Failure; Metabolic Clearance Rate; Morpholines; Perioperative Care; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes; Thrombocytopenia; Thrombosis; Vitamin K | 2014 |
[The new oral anticoagulants in special populations].
Topics: Administration, Oral; Age Factors; Anticoagulants; Benzimidazoles; Contraindications; Dabigatran; Embolism; Humans; Morpholines; Obesity; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thrombosis | 2012 |
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes | 2013 |
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2014 |
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Humans; Prospective Studies; Randomized Controlled Trials as Topic; Renal Insufficiency; Venous Thromboembolism | 2012 |
The laboratory and the new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Hemostasis; Humans; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes | 2013 |
Acute management of bleeding in patients on novel oral anticoagulants.
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Plasma; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Dialysis; Renal Insufficiency; Risk Factors; Rivaroxaban; Thiophenes | 2013 |
5 trial(s) available for dabigatran and Kidney Failure
| Article | Year |
|---|---|
Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement.
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Renal Insufficiency; Treatment Outcome; Venous Thromboembolism | 2016 |
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Area Under Curve; Blood Coagulation; Cross-Over Studies; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Female; Half-Life; Humans; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Partial Thromboplastin Time; Renal Insufficiency; Time Factors | 2017 |
An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery.
Topics: Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Dabigatran; Europe; Female; Humans; Male; Middle Aged; Renal Insufficiency; Venous Thromboembolism; White People | 2016 |
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antithrombins; Blood Coagulation; Dabigatran; Double-Blind Method; Epitopes; Healthy Volunteers; Hemorrhage; Humans; Luminescence; Middle Aged; Renal Insufficiency; Treatment Outcome; Young Adult | 2017 |
Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Area Under Curve; Benzimidazoles; Creatinine; Dabigatran; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Pyridines; Renal Dialysis; Renal Insufficiency; Severity of Illness Index | 2010 |
23 other study(ies) available for dabigatran and Kidney Failure
| Article | Year |
|---|---|
Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Blood Coagulation; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Renal Insufficiency; Treatment Outcome | 2019 |
Redistribution of dabigatran after idarucizumab administration in a 90-year-old woman with renal failure due to persistent large intestinal bleeding.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Renal Insufficiency | 2019 |
Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure.
Topics: Aged; Blood Coagulation; Cough; Dabigatran; Drug Interactions; Dyspnea; Factor Xa Inhibitors; Fatigue; Fever; Humans; Male; Ranolazine; Renal Insufficiency | 2019 |
Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study.
Topics: Age Factors; Aged; Anticoagulants; Antithrombins; Blood Coagulation; Comorbidity; Dabigatran; Female; Global Health; Humans; Kidney Function Tests; Male; Practice Patterns, Physicians'; Renal Insufficiency; Risk Adjustment; Severity of Illness Index; Venous Thromboembolism; Warfarin | 2021 |
Monitoring the use of dabigatran etexilate for stroke prevention: compliance with renal function guidelines.
Topics: Aged; Aged, 80 and over; Antithrombins; Creatinine; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Middle Aged; Native Hawaiian or Other Pacific Islander; New Zealand; Primary Health Care; Renal Insufficiency; Retrospective Studies; Socioeconomic Factors; Stroke | 2020 |
How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group.
Topics: Administration, Oral; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Italy; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Surveys and Questionnaires; Thiazoles; Thrombosis; Treatment Outcome | 2021 |
Renal failure caused by a partly calcified aortic aneurysm in a patient with dabigatran therapy: A case report.
Topics: Aged, 80 and over; Antithrombins; Aortic Aneurysm; Dabigatran; Diagnosis, Differential; Humans; Male; Melena; Renal Insufficiency; Vascular Calcification | 2017 |
Late rebound of dabigatran levels after idarucizumab reversal in two patients with severe renal failure.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Renal Insufficiency; Severity of Illness Index; Time Factors | 2017 |
Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Pyrazoles; Pyridones; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke; Time Factors; Treatment Outcome; United States; Vitamin K; Young Adult | 2017 |
Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Creatinine; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Female; Guideline Adherence; Humans; Kidney Function Tests; Male; Multivariate Analysis; Odds Ratio; Practice Guidelines as Topic; Pyrazoles; Pyridones; Registries; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke | 2018 |
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination.
Topics: Animals; Antibodies, Monoclonal, Humanized; Blood Coagulation; Dabigatran; Humans; Kidney; Rats; Renal Elimination; Renal Insufficiency; Swine | 2018 |
Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Australia; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Partial Thromboplastin Time; Renal Insufficiency; Retrospective Studies; Thrombin Time | 2019 |
A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients.
Topics: Adult; Antithrombins; Dabigatran; Glucuronides; Humans; Models, Biological; Renal Insufficiency | 2019 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Renal Insufficiency; Research Design; Selection Bias; Stroke; Warfarin | 2013 |
Impaired renal function and bleeding in elderly treated with dabigatran.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Dosage Calculations; Female; Hemorrhage; Humans; Kidney; Kidney Function Tests; Male; Renal Insufficiency; Stroke | 2014 |
Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose.
Topics: Aged; Antithrombins; Benzimidazoles; Dabigatran; Drug Overdose; Hemodiafiltration; Humans; Male; Metabolic Clearance Rate; Polypharmacy; Pyridines; Renal Insufficiency; Severity of Illness Index; Treatment Outcome | 2014 |
[Serious bleeding as a consequence of accumulation of dabigatran caused by renal failure].
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Male; Renal Dialysis; Renal Insufficiency | 2014 |
Left subconjunctival hemorrhage · renal dysfunction · international normalized ratio of 4.5 · Dx?
Topics: Aged; Antithrombins; Atrial Fibrillation; Conjunctival Diseases; Dabigatran; Drug Interactions; Drug Substitution; Eye Hemorrhage; Female; Humans; Immunosuppressive Agents; International Normalized Ratio; Liver Transplantation; Renal Insufficiency; Tacrolimus; Treatment Outcome | 2015 |
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Comorbidity; Creatinine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke; Venous Thromboembolism | 2016 |
Safety of low-dose dabigatran in patients with atrial fibrillation and mild renal insufficiency.
Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Partial Thromboplastin Time; Renal Insufficiency; Retrospective Studies; Risk Factors; Stroke; Thromboembolism | 2017 |
[Renal function and plasma dabigatran level measured at trough by diluted thrombin time assay].
Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Creatinine; Dabigatran; Drug Monitoring; Female; Humans; Kidney Function Tests; Male; Middle Aged; Partial Thromboplastin Time; Renal Insufficiency; Thrombin Time; Young Adult | 2017 |
Bleeding with dabigatran (Pradaxa).
Topics: Antithrombins; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Hemorrhage; Humans; Pyridines; Renal Insufficiency; Stroke | 2011 |
Initial experience with dabigatran etexilate at Auckland City Hospital.
Topics: Adult; Aged; Aged, 80 and over; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Female; Hemorrhage; Hospitals, Urban; Humans; Male; Middle Aged; New Zealand; Patient Selection; Pyridines; Renal Insufficiency; Retrospective Studies | 2012 |